

REMARKS

I. THE AMENDMENTS OF THE CLAIMS

Claims 29-48 are pending in the instant application. With this Amendment, Claims 29-48 have been amended to delete the expression "extrachromosomal," as suggested by the Examiner. No new matter is added by these amendments, and they are believed to place the claims in condition for allowance. Accordingly, entry thereof into the instant application is respectfully requested. For the convenience of the Examiner, a copy of the claims as pending after entry of this Amendment is attached hereto as Exhibit A.

II. THE REJECTIONS

A. The Rejection Under 35 U.S.C. § 112, First Paragraph, Should Be Withdrawn

Claims 29-48 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly lacking adequate written description. Specifically, the Examiner objects to the recitation of "extrachromosomal." While not agreeing with the propriety of this rejection, in order to expedite allowance of the claims, Applicants have deleted the word "extrachromosomal" from each rejected claim, thereby obviating this rejection. Accordingly, Applicants respectfully request that the rejection of Claims 29-48 under 35 U.S.C. §112, first paragraph, be withdrawn.


CONCLUSION

Applicants submit Claims 29-48, as amended, meet all of the criteria for patentability and are in condition for allowance. An early indication of the same is therefore respectfully requested.

No fee is believed due in connection with this Amendment. However, the Commissioner is authorized to charge any required fee or credit any overpayment to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date March 13, 2000



Brian M. Poissant

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, N.Y. 10036-2711

(212) 790-9090



28,462
(Reg. No.) 42067

Exhibit A

Claims As Pending After Entry Of The Instant Amendments

29. (Amended) An isolated polynucleotide comprising at least 8 consecutive bases and up to about 100 consecutive bases of the sequence shown in SEQ ID NOS:1 or 2, or the complement thereof, wherein said isolated polynucleotide includes at least one polymorphic site shown in Table 1.

30. (Amended) The isolated polynucleotide of Claim 29, wherein the polymorphic site is at base 61465 of SEQ ID NO:1.

31. (Amended) The isolated polynucleotide of Claim 29, wherein the polymorphic site is at base 35983 of SEQ ID NO:1.

32. (Amended) A pair of isolated polynucleotides as in Claim 29.

33. (Amended) An isolated polynucleotide comprising at least 18 consecutive bases and up to about 100 consecutive bases of the sequence shown in SEQ ID NOS:1 or 2, or the complement thereof, wherein said isolated polynucleotide includes at least one polymorphic site shown in Table 1.

34. (Amended) The isolated polynucleotide of Claim 33, wherein the polymorphic site is at base 61465 of SEQ ID NO:1.

35. (Amended) The isolated polynucleotide of Claim 33, wherein the polymorphic site is at base 35983 of SEQ ID NO:1.

36. (Amended) A pair of isolated polynucleotides as in Claim 33.

37. (Amended) An isolated polynucleotide comprising a fragment of at least about 100 consecutive bases and up to about 235 consecutive kilobases of the sequence shown in SEQ ID NOS:1 or 2, or the complement thereof, wherein said isolated polynucleotide includes at least one polymorphic site shown in Table 1.

38. (Amended) The isolated polynucleotide of Claim 37 which is cDNA.

39. (Amended) The isolated polynucleotide of Claim 37 which is RNA.

40. (Amended) The isolated polynucleotide of Claim 37 which is genomic DNA.

41. (Amended) An isolated polynucleotide comprising a fragment of at least about 300 consecutive bases and up to about 235 consecutive kilobases of the sequence shown in SEQ ID NOS:1 or 2, or the complement thereof, wherein said isolated polynucleotide includes at least one polymorphic site shown in Table 1.

42. (Amended) The isolated polynucleotide of Claim 41 which is cDNA.

43. (Amended) The isolated polynucleotide of Claim 41 which is RNA.

44. (Amended) The isolated polynucleotide of Claim 41 which is genomic DNA.

45. (Amended) A kit comprising an isolated polynucleotide of Claim 29.

46. (Amended) A kit comprising an isolated polynucleotide of Claim 33.

47. (Amended) A kit comprising at least one pair of isolated polynucleotides as in Claim 32.

48. (Amended) A kit comprising at least one pair of isolated polynucleotides as in Claim 36.